南模生物: 2025年半年度募集资金存放与使用情况的专项报告

Fundraising Overview - The company raised a total of RMB 1,649,319,958.00 by issuing 19,490,900 shares at a price of RMB 84.62 per share, with a net amount of RMB 1,467,876,199.92 after deducting issuance costs [1][2] - As of June 30, 2025, the total net amount of raised funds was RMB 146,787.62 million, with RMB 146,308.22 million invested in projects and RMB 1,794.24 million in net interest income [1][2] Fund Management - The company established a management method for the raised funds, adhering to regulations to ensure proper management and usage, including a dedicated account storage system [1][2] - Six dedicated accounts for the raised funds have been closed as of June 30, 2025, indicating a complete utilization of the funds [1][2] Fund Utilization - The company did not have any idle funds or temporary use of idle funds for working capital during the reporting period [1][2] - All investment projects funded by the raised capital, including the "Gene Modification Model Resource Library" and "Humanized Antibody Mouse Model Development," have been completed [4][5] Cash Management - The company approved the use of up to RMB 80 million of excess and idle funds for cash management, allowing for cyclical use within a 12-month period starting from February 1, 2024 [1][2] Compliance and Reporting - The company confirmed that all disclosed information regarding the use of raised funds is timely, truthful, accurate, and complete, with no significant violations in fund usage [1][2]